{"id":20090,"date":"2023-09-13T10:30:04","date_gmt":"2023-09-13T10:30:04","guid":{"rendered":"https:\/\/clinlabint.com\/?p=20090"},"modified":"2023-09-13T10:30:04","modified_gmt":"2023-09-13T10:30:04","slug":"waters-launches-xbridge-premier-gtx-beh-sec-columns-for-gene-therapy-applications","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/waters-launches-xbridge-premier-gtx-beh-sec-columns-for-gene-therapy-applications\/","title":{"rendered":"Waters launches XBridge Premier GTx BEH SEC Columns for gene therapy applications"},"content":{"rendered":"
\n

\r\n\"Bio-Rad<\/a>\r\n<\/p>\n<\/div><\/section><\/div>

<\/p>\n<\/div><\/section>
\n

Waters launches XBridge Premier GTx BEH SEC Columns for gene therapy applications<\/h1>\/ in Product News<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\n

Waters Corporation has introduced the first in a new line of size exclusion chromatography (SEC) columns aimed at improving the analysis while lowering the cost of gene therapies, specifically adeno-associated viral (AAV) vectors. The new Waters XBridge Premier GTx BEH SEC columns doubles the speed of measuring the potency and safety of AAVs. Combining the columns with light scattering technologies from its Wyatt Technology portfolio deepens the level of information acquired from a single experiment and optimizes the manufacturing of these novel gene delivery vehicles.<\/strong><\/p>\n

<\/p>\n

\u201cWe are witnessing a revolution in medicine thanks to gene therapies like AAVs,\u201d remarked said Erin Chambers, Vice President, Consumables and Lab Automation, Waters Corporation. \u201cA small quantity of a gene therapy, such as one of the best-selling eye treatments, can retail for more than $400,000 per eye. This makes it imperative that process and formulation development tests measure multiple attributes of the drug at once while consuming as little of it as possible. It\u2019s why Waters\u2019 low adsorption, high-efficiency XBridge Premier GTx BEH SEC columns are such a good choice for process development, formulation studies, regulatory filing support, along with ongoing process monitoring as well as quality control.\u201d<\/p>\n

AAVs are modified viruses made in bioreactors by living cells and are the premier vehicle for carrying therapeutic genes into human cells. Waters scientists have developed a fast and efficient multi-attribute quantification method of characterizing AAVs that features the following Waters products:
\n\u2022 ACQUITY Premier UPLC Systems or Arc Premier HPLC Systems
\n\u2022 XBridge Premier GTx BEH SEC 450\u00c5 2.5 \u03bcm columns
\n\u2022 Arc Premier 2489 UV\/Visible detector or 2998 photodiode array detector
\n\u2022 Wyatt DAWN multi-angle light scattering detector
\n\u2022 Wyatt Optilab differential refractive index detector<\/p>\n

For more information, visit:
\nhttps:\/\/www.waters.com\/nextgen\/us\/en\/shop\/columns\/186010587-xbridge-premier-gtx-beh-sec-column-450-a-25–m-78-x-300-mm-1-pk.html<\/a><\/p>\n

Digital issue: Please click here<\/a> for more information<\/p>\n<\/div><\/section>
\n

\"\"<\/div><\/div><\/div>
\n
\n